Michael S Wyzga
CIK 1201256 · Chief Executive Officer · last filed 2026-06-11
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
EXAS price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
201 BROADWAY, 6TH FLOOR
CAMBRIDGE, MA 02139
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TVRD | Director | — | $0.84 | — | $0 | 2 | 2026-06-11 |
| MREO | Director | 25,050 | $0.28 | $6.9K | $0 | 4 | 2026-02-27 |
| XFOR | Director | 5,555 | $3.25 | $18.1K | $29.9K | 10 | 2026-01-05 |
| IVVD | Director | — | $0.59 | — | $0 | 1 | 2023-05-25 |
| LogicBio Therapeutics, Inc. (LOGC) Delisted | Director | 0 | $7.06 | $0 | $0 | 7 | 2022-11-17 |
| Invivyd, Inc. (ADGI) Delisted | Director | — | $4.64 | — | $0 | 2 | 2022-06-24 |
| EXACT SCIENCES CORP (EXAS) Delisted | Director | 2,558 | $104.91 | $268.4K | -$3.68M | 12 | 2021-03-02 |
| AKBA | Director | 1,500 | $0.64 | $966 | $25.5K | 5 | 2018-06-15 |
| IDENIX PHARMACEUTICALS INC (IDIX) Delisted | Director | — | — | — | $0 | 4 | 2014-08-05 |
| GENZ | Executive VP and CFO | 0 | $37.37 | $0 | -$2.94M | 8 | 2011-04-06 |
| Altus Pharmaceuticals Inc. (ALTU) Delisted | Director | — | $10.12 | — | $0 | 4 | 2009-07-02 |
Recent Filings · Page 3 of 7
66 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-03-02 | EXACT SCIENCES CORP (EXAS) Delisted | Mixed | −8,913 | -$2.20M | EDGAR |
| 2021-01-04 | LogicBio Therapeutics, Inc. (LOGC) Delisted | Exer (M) | +3,141 | $0 | EDGAR |
| 2020-07-24 | EXACT SCIENCES CORP (EXAS) Delisted | Grant (A) | +2,558 | $0 | EDGAR |
| 2020-06-23 | LogicBio Therapeutics, Inc. (LOGC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-06-11 | XFOR | Grant (A) | — | $0 | EDGAR |
| 2019-12-20 | LogicBio Therapeutics, Inc. (LOGC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-08-02 | EXACT SCIENCES CORP (EXAS) Delisted | Mixed | −2,500 | -$522.2K | EDGAR |
| 2019-07-26 | EXACT SCIENCES CORP (EXAS) Delisted | Grant (A) | +2,801 | $0 | EDGAR |
| 2019-04-02 | XFOR | Grant (A) | — | $0 | EDGAR |
| 2019-03-14 | XFOR | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.